What question did this study set out to answer?

The aim is to evaluate the effectiveness and persistence of different integrase strand transfer inhibitors in a real-world cohort.

March 10, 20260 citations

View Full Paper

Real-world use of second-generation integrase strand transfer inhibitors (INSTI) as switch therapy in the prospective ANRS-CO3-AquiVIH-NA cohort.

OLOlivier Leleux APA Peyrouny-Mazeau APAntoine PerrierCentre National de la Recherche Scientifique

Key Points

The aim is to evaluate the effectiveness and persistence of different integrase strand transfer inhibitors in a real-world cohort.
Conducted a prospective cohort analysis over 18 months
Examined treatment outcomes for B/F/TAF, DTG/RPV, DTG/3TC, and DTG/3TC/ABC
Assessed viral suppression and treatment persistence among participants
Treatment persistence at 18 months was similar for B/F/TAF, DTG/RPV, and DTG/3TC
DTG/3TC/ABC showed significantly lower treatment persistence
All regimens maintained high levels of viral suppression throughout the study

Abstract

In this real-world cohort, treatment persistence 18 months after therapy switch was similar for B/F/TAF, DTG/RPV and DTG/3TC, but significantly lower for DTG/3TC/ABC. All regimens maintained high levels of viral suppression. Furthermore, the cohort illustrates the disease burden experienced by middle-aged and elderly people living with HIV and highlights the importance of adapting ART to the specific needs of this population.

Ask AI

Helpful

Bookmark

View Full Paper

Ask AI

Helpful

Bookmark

View Full Paper

Real-world use of second-generation integrase strand transfer inhibitors (INSTI) as switch therapy in the prospective ANRS-CO3-AquiVIH-NA cohort.

Key Points

Abstract

Cite This Study

Also Consider

Also Consider